Boehringer Ingelheim inks third collab in four years with Danish biotech company

Another deal has fallen into place between Boehringer Ingelheim and the Danish biotech and contract research firm Gubra. The parties have entered into lucrative deals in the past, but will not disclose the financial terms underlying the new agreement.
Photo: Gubra / PR
Photo: Gubra / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

Danish biotech and contract research firm Gubra has signed a new agreement with German pharmaceutical giant Boehringer Ingelheim on the development of peptide compounds for treating obesity, according to a joint press announcement from the companies.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading